Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 3Terminated 3Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Renal Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Childhood Solid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × talazoparib × Clear all
NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

University of Michigan Rogel Cancer Center

Phase 1 Completed
26 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Completed
73 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡